Moleculin Biotech Earnings Estimate

MBRX
 Stock
  

USD 1.55  0.02  1.31%   

Many public companies, such as Moleculin Biotech, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Moleculin Biotech's earnings estimates, investors can diagnose different trends across Moleculin Biotech's analyst sentiment over time as well as compare current estimates against different timeframes.
Moleculin Biotech is projected to generate -0.71 in earnings per share on the 31st of December 2021. Moleculin Biotech earnings estimates module stress-tests analyst consensus about projected Moleculin Biotech CS EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Additionally, see Stocks Correlation.
  
Refresh
Profit Margin is likely to drop to -8.54 in 2022

Moleculin Biotech Earnings Estimation Breakdown

Calculation of earning per share of Moleculin Biotech is based on official Zacks consensus of 1 analysts regarding Moleculin Biotech future annual earnings. Given the historical accuracy of 67.78%, the future earnings per share of Moleculin Biotech is estimated to be -0.71 with the lowest and highest values of -0.79 and -0.63, respectively. Please note that this consensus of annual earnings estimates for Moleculin Biotech CS is an estimate of EPS before non-recurring items and including employee stock options expenses
  Current EPS -0.7
-0.79
Lowest
Expected EPS -0.71
-0.63
Highest

Moleculin Biotech Earnings Projection Consensus

Suppose the current estimates of Moleculin Biotech's value are higher than the current market price of the Moleculin Biotech stock. In this case, investors may conclude that Moleculin Biotech is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Moleculin Biotech's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021

1

67.78%

-0.7

-0.71

Moleculin Biotech Earnings per Share Projection vs Actual

Actual Earning per Share of Moleculin Biotech refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Moleculin Biotech CS predict the company's earnings will be in the future. The higher the earnings per share of Moleculin Biotech, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Moleculin Biotech Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Moleculin Biotech, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Moleculin Biotech should always be considered in relation to other companies to make a more educated investment decision.

Moleculin Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Moleculin Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-05-11
2022-03-31-0.21-0.24-0.0314 
2022-03-24
2021-12-31-0.21-0.090.1257 
2021-11-10
2021-09-30-0.2067-0.212-0.0053
2021-08-11
2021-06-30-0.1867-0.1904-0.0037
2021-05-12
2021-03-31-0.24-0.2761-0.036115 
2021-03-24
2020-12-31-0.57-1.9871-1.4171248 
2020-11-12
2020-09-30-0.56-0.5991-0.0391
2020-08-12
2020-06-30-0.54-0.50570.0343
2020-05-11
2020-03-31-0.6-0.6072-0.0072
2020-03-19
2019-12-31-0.6-0.6654-0.065410 
2019-11-12
2019-09-30-0.52-0.5628-0.0428
2019-08-16
2019-06-30-0.72-0.51360.206428 
2019-05-13
2019-03-31-0.54-0.84-0.355 
2019-02-21
2018-12-31-0.6-0.60
2018-11-13
2018-09-30-0.78-0.480.338 
2018-08-10
2018-06-30-0.84-1.2-0.3642 
2018-05-14
2018-03-31-0.84-0.6780.16219 
2018-03-28
2017-12-31-0.72-1.0103-0.290340 
2017-11-13
2017-09-30None-0.84None
2017-08-14
2017-06-30None-0.1917None
2017-04-03
2017-03-31-0.11-0.12-0.01
2016-11-21
2016-09-30-0.11-0.1237-0.013712 
2016-08-15
2016-06-30None-0.0832None

About Moleculin Biotech Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Moleculin Biotech earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Moleculin Biotech estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Moleculin Biotech fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Accumulated Retained Earnings Deficit-72.8 M-74.7 M
Earning Before Interest and Taxes EBIT-15.9 M-16.3 M
Earnings per Basic Share(0.59) (0.64) 
Earnings per Diluted Share(0.59) (0.64) 
Price to Earnings Ratio(3.15) (3.40) 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-15.7 M-16.1 M
Earnings before Tax-15.9 M-16.3 M
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.

Moleculin Biotech Investors Sentiment

The influence of Moleculin Biotech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Moleculin. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moleculin Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moleculin Biotech's short interest history, or implied volatility extrapolated from Moleculin Biotech options trading.

Current Sentiment - MBRX

Moleculin Biotech Investor Sentiment

Most of Macroaxis users are now bullish on Moleculin Biotech CS. What is your trading attitude regarding investing in Moleculin Biotech CS? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moleculin Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
41.2 M
Return On Assets
-0.17
Return On Equity
-0.23
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.